Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.81 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | NPC1 | O15118 | 8/20 | 0.74 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.70 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862297 | 0.90 | RXFP1 (0.94) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL4251968 | 0.90 | RXFP1 (0.94) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL30455725 | 0.87 | NPC1 (0.76) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL29800540 | 0.85 | NPC1 (1.00) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL2176828 | 0.85 | NPC1 (1.00) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL10055020 | 0.85 | NPC1 (0.94) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL4251405 | 0.84 | RXFP1 (0.74) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL1816127 | 0.84 | MEN1 (0.84) | RAB9ANPC1KCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL4249753 | 0.84 | KCNK3 (0.92) | RXFP1RAB9ANPC1NLRP3ALDH1A1 | |
| SCHEMBL1811681 | 0.83 | MEN1 (0.63) | RXFP1RAB9ANPC1KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | RXFP1 170/4885RAB9A 733/4885NPC1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.